ARTICLE | Company News
Eureka Therapeutics, Memorial Sloan Kettering, Juno Therapeutics deal
August 8, 2016 7:00 AM UTC
Memorial Sloan and Eureka granted Juno exclusive, worldwide rights to binding domains against three multiple myeloma (MM) targets. Juno will incorporate the targets into chimeric antigen receptor (CAR...